Is Eris Lifesciences the correct prescription for you?
With a predominant focus on the domestic formulations market, a robust portfolio of largely prescription-based drugs, and a tilt towards a promising chronic portfolio, the company seems fundamentally strong.
GST Watch: In staples and durables, expect two quarters of supply disruption
Why this midcap company could be spinning its way to the top
Although Nitin Spinners doesn’t have a unique product line or process, what puts it on the map for investors is its performance potential for the forthcoming years.
Bumpy ride for commercial vehicle companies far from over
Medium and heavy commercial vehicle companies would be staring at a difficult earnings season and the impact can linger on for a couple of more months.
Do FIIs and DIIs really drive the markets? Here’s what correlations say
Investors should clearly select stocks on merit rather than blindly following flow patterns. Tracking smart money in the long term doesn’t necessarily generate smart returns.
Key lesson from FY17 IPOs: Don’t fret if you miss the bus
The key takeaway from our analysis for the prospective investor is that if he has missed the IPO bus last year, it makes sense to ride it with good IPOs in FY18.
- Miles To Go | COVID-19 Omicron variant: Update on International Travel Guidelines Watch more
- Ideas For Profit | Market correction offers favourable opportunity to buy these auto stocks Watch more
- Twitter gets Indian-origin CEO as co-founder Jack Dorsey resigns: who is Parag Agrawal? Watch more
- New Covid variant may decrease vaccine’s ability to neutralise the virus: Dr Gagandeep Kang Watch more